Quent Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Quent Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.62K	Sell	166 -69	-29%	-$599	﹤0.01%	1500
2026 Q1	$1.31K	Hold	235	–	–	﹤0.01%	1423
2025 Q4	$1.73K	Buy	235 +4	+2%	+$24	﹤0.01%	1405
2025 Q3	$1.51K	Buy	+231	New	+$1.24K	﹤0.01%	1288
2025 Q2	–	Sell	-231	Closed	-$864	–	804
2025 Q1	$864	Sell	231 -2	-0.9%	-$17	﹤0.01%	1228
2024 Q4	$2.36K	Hold	233	–	–	﹤0.01%	1149
2024 Q3	$2.9K	Hold	233	–	–	﹤0.01%	1189
2024 Q2	$3.03K	Buy	+233	New	+$3.86K	﹤0.01%	1166
2023 Q2	–	Sell	-26	Closed	-$1.5K	–	1339
2023 Q1	$1.5K	Hold	26	–	–	﹤0.01%	1200
2022 Q4	$1.31K	Buy	26 +24	+1,200%	+$1.66K	﹤0.01%	1198
2022 Q3	$0	Hold	2	–	–	﹤0.01%	1246
2022 Q2	$0	Hold	2	–	–	﹤0.01%	1246
2022 Q1	$0	Buy	+2	New	+$249	﹤0.01%	1291

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quent Capital's KPTI Position: Q2 2026 in Review

Quent Capital reduced its Karyopharm Therapeutics (KPTI) stake by 29% in Q2 2026, selling an estimated $599 and leaving 166 shares worth $1.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Quent Capital first reported a position in KPTI in Q1 2022 and has held it in 13 quarters since. The position peaked at $3.03K in Q2 2024. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Quent Capital held 166 shares of Karyopharm Therapeutics worth $1.62K as of Q2 2026.
Quent Capital sold 69 Karyopharm Therapeutics shares in Q2 2026, an estimated $599.
Karyopharm Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1500 holding.
Quent Capital first reported a position in Karyopharm Therapeutics in Q1 2022 and has held it in 13 quarters since.
Quent Capital's Karyopharm Therapeutics position peaked at $3.03K in Q2 2024.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.